Vaccine for mystery swine disease and method for diagnosis thereof
AssigneeBoehringer Ingelheim Animal Health, Inc.
InventorsJames E. Collins, David A. Benfield, Danny W. Chladek, Louis L. Harris, David E. Gorcyca
Life of this patent
Estimating the term…
Abstract
The invention includes a vaccine and sera for treatment of Mystery Swine Disease (MSD), a method for producing the vaccine, methods for diagnosis of MSD, a viral agent that will mimic “mystery swine disease” and antibodies to the viral agent useful in diagnosis and treatment of MSD. The serum contains mammalian antibodies which are effective in treating MSD.
Claims37
A vaccine suitable for use in prevention of mystery swine disease, comprising:
- an inactivated or attenuated infectious agent derived from swine tissue infected with mystery swine disease in combination with a pharmaceutical carrier.
A serum suitable for treatment of swine infected with mystery swine disease, comprising:
- the semi-purified blood serum of a mammal inoculated with an infectious agent derived from swine tissue infected with mystery swine disease.
A method for diagnosis of mystery swine disease in swine, comprising:
- obtaining a lung tissue sample from the swine,
- forming a liquid homogenate of the sample,
- adding the liquid homogenate to a vessel for immobilizing a viral material to form an immobilized mixture,
- adding to the immobilized mixture a nonswine, mammalian species antibody serum to mystery swine disease to form a complex,
- adding a labeled anti-species antibody to detect the complex.
A method for diagnosis of mystery swine disease in swine, comprising:
- forming a liquid homogenate of a sample suspected of harboring the mystery swine disease infectious agent tissue sample from the swine,
- adding to the liquid homogenate an immunoreactive antibody which is immunospecific for mystery swine disease virus,
- detecting the presence of a precipitate of an antibody-antigen complex.
A method of making a MSD vaccine containing an inactivated or attenuated MSD infectious agent, the method comprising:
- identifying swine lung tissue having thickened aveolar septae, degenerating cells and debris in aveolar spaces;
- homogenizing the swine lung tissue with a pharmaceutically acceptable aqueous solution to form a mixture;
- filtering the mixture through a series of filters to produce a filtered homogenate containing the MSD infectious agent;
- and
- inactivating or attenuating the MSD infectious agent in the filtered homogenate to produce the MS vaccine.
A biologically pure culture of a fastidious, non-hemagglutinating, enveloped RNA virus, said culture being capable of affecting swine infertility and respiratory disease in swine, together with all zoopathogenic mutants thereof.
A monoclonal antibody produced by a murine derived hybrid cell line wherein said antibody is capable of specifically binding to at least one antigenic determinant of a fastidious non-hemagglutinating, enveloped RNA virus, capable of affecting swine infertility and respiratory disease in swine.
A biologically pure culture of swine infertility and respiratory syndrome virus, ATCC VR-2332, said culture being capable of affecting swine infertility and respiratory disease in swine, together with all zoopathogenic mutants thereof.
A vaccine composition comprising modified, live swine infertility and respiratory syndrome virus, ATCC VR-2332, and a pharmaceutically acceptable carrier, which virus has been modified to render the virus non-zoopathogenic in swine.
A vaccine composition comprising killed or inactivated swine infertility and respiratory syndrome, ATCC VR-2332, and a pharmaceutically acceptable carrier.
A method of growing and isolating swine infertility and respiratory syndrome virus, ATCC VR-2332, which comprises inoculating the virus on a full or partial sheet of simian cells in the presence of serum in a suitable growth medium and incubating the inoculated cell sheet at about 34° C. to 37° C. until CPE is observed.
Dependencies are inferred from the claim text.